Association of SGLT2 inhibitors and urogenital infections in patients attending a tertiary care hospital: a prospective observational study
DOI:
https://doi.org/10.18203/2349-3933.ijam20243814Keywords:
Blood sugar, Dapagliflozin, Diabetes, HbA1c, Mycotic infections, Oral Hypoglycaemics, SGLT2 inhibitors, Urogenital infections, UGI, Bacteriuria, UrethritisAbstract
Background: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are known for efficacy in managing blood sugar levels in type 2 diabetes and also improving cardiovascular and renal outcomes. However, increased risk of urogenital infections (UGIs) remains a significant concern in their safety profile. This study aimed to investigate the association between SGLT2i therapy and UGIs in a real-world clinical set up of a tertiary care centre in India. The key hypothesis was SGLT2i use is associated with incidence of UGIs while the secondary hypothesis included the relationship of the incidence of risk with the dose.
Methods: This was a six-month prospective observational study, that enrolled 309 adults ≥18 years of age, who were newly prescribed SGLT2 inhibitors, particularly Dapagliflozin 5 mg and 10 mg from October 2023. The incidence of UGIs was assessed through patient interviews and medical records during the follow up from 2 weeks of initiation. UGIs were defined as clinical manifestations that resolved on SGLT2i discontinuation or appropriate treatment.
Results: Of 309 initiators, 300 patients were followed up. 9 patients didn’t follow up in OPD. From these, 58 (19.3%) patients developed UGIs, comprising of 47 (15.6%) bacterial infections and 11 (3.6%) UGIs of fungal origin. The association was performed on basis of logistic regression analysis which revealed a statistically significant association of UGIs with the prescription of SGLT2i. Higher doses of SGLT2 inhibitors was observed to be associated with significantly increasing the risk of UGIs (p<0.05). No significant risk factors such as body mass index (BMI), age, sex, HbA1c or educational status were identified to have significant associations with UGI occurrence.
Conclusions: This study highlights a clinically relevant association between SGLT2i use and urogenital infections.
Metrics
References
Roglic G. WHO Global report on diabetes: A summary. Int J Noncommun Dis. 2016;1(1):3-8.
Varshney N, Billups SJ, Saseen JJ, Fixen CW. Sodium-glucose cotransporter-2 inhibitors and risk for genitourinary infections in older adults with type 2 diabetes. Therap Adv Drug Safe. 2021;12:2042098621997703.
Hou YC, Zheng CM, Yen TH, Lu KC. Molecular mechanisms of SGLT2 inhibitors on cardiorenal protection. Int J Mol Sci. 2020;21(21):7833.
Ferwani P, Maldar A, Shah N, Chauhan P, Chadha M. Prevalence of bacterial urinary tract infection among patients with type 2 diabetes mellitus on sodium-glucose cotransporter-2 inhibitors: a prospective real-world setting study. J ASEAN Fed Endocr Soc. 2022;37(2):5-8.
Thong KY, Yadagiri M, Barnes DJ, Morris DS, Chowdhury TA, Chuah LL, et al. ABCD Nationwide dapagliflozin audit contributors. clinical risk factors predicting genital fungal infections with sodiumglucose cotransporter 2 inhibitor treatment: the abcd nationwide dapagliflozin audit. Prim Care Diabetes. 2018;12(1):45-50.
Johnsson KM, Ptaszynska A, Schmitz B, Sugg J, Parikh SJ, List JF. Clinical outcomes of sodium-glucose cotransporter-2 inhibitors in patients with type 2 Diabetes Mellitus: An observational study from Pakistan. Pak J Med Sci. 2021;37(5):1342-6.
Guo L, Wang J, Li L, Yuan L, Chen S, Wang H, et al. A multicentre, prospective, non-interventional study evaluating the safety of dapagliflozin in patients with type 2 diabetes in routine clinical practice in China (DONATE). BMC Med. 2023;21(1):212.
Ko S, Kim H, Shinn J, Byeon SJ, Choi JH, Kim HS. Estimation of sodium-glucose cotransporter 2 inhibitor-related genital and urinary tract infections via electronic medical record-based common data model. J Clin Pharm Ther. 2021;46(4):975- 83.
Filippatos TD, Liberopoulos EN, Elisaf MS. Dapagliflozin in patients with type 2 diabetes mellitus. Ther Adv Endocrinol Metab. 2015;6(1):29-41.
Uitrakul S, Aksonnam K, Srivichai P, Wicheannarat S, Incomenoy S. The incidence and risk factors of urinary tract infection in patients with type 2 diabetes mellitus using SGLT2 inhibitors: a real-world observational study. Medicines (Basel). 2022;9(12):59.
Lega IC, Bronskill SE, Campitelli MA, Guan J, Stall NM, Lam K, et al. Sodium glucose cotransporter 2 inhibitors and risk of genital mycotic and urinary tract infection: A population-based study of older women and men with diabetes. Diabetes Obes Metab. 2019;21(11):2394-404.
Ghosh A, Gupta R, Singh P, Dutta A, Misra A. Sodium‐glucose cotransporter‐2 inhibitors in patients with type 2 diabetes in North India: A 12‐month prospective study in real‐world setting. Int J Clin Prac. 2018;72(9):13237.
Dave CV, Schneeweiss S, Kim D, Fralick M, Tong A, Patorno E. Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract Infections: A Population-Based Cohort Study. Ann Intern Med. 2019;171(4):248-56.
Dave CV, Schneeweiss S, Patorno E. Comparative risk of genital infections associated with sodium-glucose co-transporter-2 inhibitors. Diabetes Obes Metab. 2019;21(2):434-8.
Saijo Y, Okada H, Hata S, Nakajima H, Kitagawa N, Okamura T, et al. Reasons for discontinuing treatment with sodium-glucose cotransporter 2 inhibitors in patients with diabetes in real-world settings: the KAMOGAWA-A study. J Clin Med. 2023;12(22):6993.
Downloads
Published
How to Cite
Issue
Section
